EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel By Ogkologos - August 26, 2025 331 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR FDA Approves Melphalan As a Liver-Directed Treatment for Uveal Melanoma September 8, 2023 FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High... June 13, 2025 Neoadjuvant Chemotherapy with mFOLFIRINOX Followed by Chemoradiotherapy Improves Survival in Patients... August 14, 2024 Self Destruction September 8, 2022 Load more HOT NEWS CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated... Genetic Testing for Bladder Cancer: What People With Cancer and Their... A Poet’s Autobiography of Cancer EMA Recommends Granting a Marketing Authorisation for Asciminib
